InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.825 -0.075 (-8.33%)+
Announcement
Release
24 Feb 2026 9:02AM
Price at Release
$0.900
Full Release
download
Summary
Orthocell Limited's financial report for the half-year ending 31 December 2025 highlights a net loss of AUD 5.21 million, despite generating AUD 5.42 million in revenue and achieving a gross profit of AUD 2.98 million. The company issued new shares, raising AUD 30 million, which contributed to its total equity of AUD 41.16 million at the end of the period. Key expenses included significant investments in research and development as well as administrative costs. Orthocell is optimistic about continued revenue growth in the US and new international markets, supported by a robust balance sheet and strategic investments like securing distribution rights for the PearlBone™ technology.
Key Points
  • The report covers the half-year financial period ending 31 December 2025.
  • Orthocell reported a net loss after tax of AUD 5.21 million for the period.
  • Revenue for the half-year was AUD 5.42 million, with a gross profit of AUD 2.98 million.
  • Total equity as of 31 December 2025 was AUD 41.16 million.
  • Orthocell raised AUD 30 million through the issuance of ordinary shares.
  • Significant expenses included research and development, selling & general expenses, and administration.
  • The company anticipates further growth from US market expansions and new international markets.
  • Share-based payments expense for the period amounted to AUD 1.42 million.
  • Orthocell secured a first right of refusal over global distribution rights for PearlBone™, a bone regeneration technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.